Company / Working Capital
Serina Therapeutics, Inc. Working Capital History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$2.5M
FY2025
5-year range
-$7.6M / $6.2M
FY2021-FY2025
Trend
-24.0%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $6M to $3M over the past 2 years.
Based on SEC 10-K filings.
$3M in FY2025.
Declined from $6M to $3M over the past 2 years.
Working Capital over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, working capital decreased 24.0% year-over-year.
- Peak working capital was recorded in FY2023.
- Lowest working capital in the period was in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -18.20 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.5M | -24.0% |
| FY2024 | $3.3M | -46.7% |
| FY2023 | $6.2M | +181.4% |
| FY2022 | -$7.6M | -13.2% |
| FY2021 | -$6.7M | -119.0% |
| FY2020 | -$3.1M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026